Skip to main content
Year archive

Heidelberg Pharma AG — 2008 filings

All 19 regulatory filings released by Heidelberg Pharma AG (HPHA) in 2008, sourced directly from the official regulator.

19 Filings
2008 Period
2008 filings (19)
Filing Released Lang
WILEX releases 9-month Financial Report 2008: Significant progress in development projects
Report Publication Announcement 9M 2008
2008-10-13 English
Q3 Report 2007/2008
Interim / Quarterly Report 9M 2008
2008-10-13 German
Declaration of Voting Results & Voting Rights Announcements 2008
Declaration of Voting Results & Voting Rights Announcements
2008-09-16 German
WILEX AG starts patient recruitment in Phase II breast cancer trial with its uPA inhibitor MESUPRON (WX-671)
Regulatory Filings
2008-08-11 English
WILEX AG: Patient recruitment in Phase II trial with MESUPRON (WX-671) in pancreatic cancer patients successfully completed
Regulatory Filings
2008-07-24 English
Q2 Report 2007/2008
Interim / Quarterly Report H2 2008
2008-07-17 English
WILEX reports successful first half year 2008
Earnings Release H1 2008
2008-07-14 English
WILEX AG: Phase III ARISER study with RENCAREX: patient recruitment successfully completed
Legal Proceedings Report
2008-07-03 English
WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE (CA9-SCAN)
Regulatory Filings
2008-06-06 English
WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE (CA9-SCAN)
M&A Activity
2008-06-06 English
WILEX AG: Patient recruitment started in Phase III registration trial with CA9-SCAN
Regulatory Filings
2008-05-19 English
WILEX reports successful first quarter 2008
Earnings Release Q1 2008
2008-04-10 English
Q1 Report 2007/2008
Interim / Quarterly Report Q1 2008
2008-04-10 German
WILEX AG reports a successful financial year 2007 positive outlook for 2008
Earnings Release FY 2007
2008-02-20 English
Annual Report 2006/2007
Annual Report FY 2007
2008-02-20 German
WILEX AG: FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCAN
Legal Proceedings Report
2008-02-11 English
WILEX receives US FDA approval (IND) for clinical Phase II trial with its uPA inhibitor WX-671 in metastatic breast cancer
Regulatory Filings
2008-01-28 English
WILEX AG: Phase I study with uPA inhibitor WX-UK1 successfully completed
Regulatory Filings
2008-01-25 English
Declaration of Voting Results & Voting Rights Announcements 2008
Declaration of Voting Results & Voting Rights Announcements
2008-01-04 German